 | • レポートコード：QYR2104Z5757 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、腫瘍免疫療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（腫瘍浸潤リンパ球（TIL）治療、操作T細胞受容体（TCR）療法、キメラ抗原受容体（CAR）T細胞療法、ナチュラルキラー（NK）細胞療法、その他）、用途別市場規模（バイオ医薬品会社、病院、大学、その他科学研究機関、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・腫瘍免疫療法の市場動向 ・企業の競争状況、市場シェア ・腫瘍免疫療法の種類別市場規模（腫瘍浸潤リンパ球（TIL）治療、操作T細胞受容体（TCR）療法、キメラ抗原受容体（CAR）T細胞療法、ナチュラルキラー（NK）細胞療法、その他） ・腫瘍免疫療法の用途別市場規模（バイオ医薬品会社、病院、大学、その他科学研究機関、その他） ・腫瘍免疫療法の北米市場規模2016-2027（アメリカ、カナダ） ・腫瘍免疫療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・腫瘍免疫療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腫瘍免疫療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・腫瘍免疫療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Roche、Merck、Novartis、Johnson & Johnson、GlaxoSmithKline、AbbVie、ELI Lilly、Amgen、AstraZeneca、Bristol-Mysers Squibb、Kite Pharma、Adaptimmune、Altor Bioscience Corporation、Cellectis、Juno Therapeutics、Takara Bio、Unum Therapeutics、Sunway、Junshi Bio、Cinda Bio、BeiGene） ・結論 |
Market Analysis and Insights: Global Tumor Immunotherapy Market
The global Tumor Immunotherapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor Immunotherapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumor Immunotherapy market.
Global Tumor Immunotherapy Scope and Market Size
Tumor Immunotherapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Tumor Infiltrating Lymphocyte (TIL) Treatment
Engineered T Cell Receptor (TCR) Therapy
Chimeric Antigen Receptor (CAR) T Cell Therapy
Natural Killer (NK) Cell Therapy
Other
Segment by Application
Biopharmaceutical Company
Hospital
Universities And Other Scientific Research Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Merck
Novartis
Johnson & Johnson
GlaxoSmithKline
AbbVie
ELI Lilly
Amgen
AstraZeneca
Bristol-Mysers Squibb
Kite Pharma
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Takara Bio
Unum Therapeutics
Sunway
Junshi Bio
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
1.2.3 Engineered T Cell Receptor (TCR) Therapy
1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
1.2.5 Natural Killer (NK) Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Tumor Immunotherapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Biopharmaceutical Company
1.3.3 Hospital
1.3.4 Universities And Other Scientific Research Institutions
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunotherapy Market Perspective (2016-2027)
2.2 Tumor Immunotherapy Growth Trends by Regions
2.2.1 Tumor Immunotherapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Tumor Immunotherapy Historic Market Share by Regions (2016-2021)
2.2.3 Tumor Immunotherapy Forecasted Market Size by Regions (2022-2027)
2.3 Tumor Immunotherapy Industry Dynamic
2.3.1 Tumor Immunotherapy Market Trends
2.3.2 Tumor Immunotherapy Market Drivers
2.3.3 Tumor Immunotherapy Market Challenges
2.3.4 Tumor Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunotherapy Players by Revenue
3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2016-2021)
3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2016-2021)
3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunotherapy Revenue
3.4 Global Tumor Immunotherapy Market Concentration Ratio
3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2020
3.5 Tumor Immunotherapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunotherapy Product Solution and Service
3.7 Date of Enter into Tumor Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunotherapy Breakdown Data by Type
4.1 Global Tumor Immunotherapy Historic Market Size by Type (2016-2021)
4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2022-2027)
5 Tumor Immunotherapy Breakdown Data by Application
5.1 Global Tumor Immunotherapy Historic Market Size by Application (2016-2021)
5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Tumor Immunotherapy Market Size (2016-2027)
6.2 North America Tumor Immunotherapy Market Size by Type
6.2.1 North America Tumor Immunotherapy Market Size by Type (2016-2021)
6.2.2 North America Tumor Immunotherapy Market Size by Type (2022-2027)
6.2.3 North America Tumor Immunotherapy Market Size by Type (2016-2027)
6.3 North America Tumor Immunotherapy Market Size by Application
6.3.1 North America Tumor Immunotherapy Market Size by Application (2016-2021)
6.3.2 North America Tumor Immunotherapy Market Size by Application (2022-2027)
6.3.3 North America Tumor Immunotherapy Market Size by Application (2016-2027)
6.4 North America Tumor Immunotherapy Market Size by Country
6.4.1 North America Tumor Immunotherapy Market Size by Country (2016-2021)
6.4.2 North America Tumor Immunotherapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Tumor Immunotherapy Market Size (2016-2027)
7.2 Europe Tumor Immunotherapy Market Size by Type
7.2.1 Europe Tumor Immunotherapy Market Size by Type (2016-2021)
7.2.2 Europe Tumor Immunotherapy Market Size by Type (2022-2027)
7.2.3 Europe Tumor Immunotherapy Market Size by Type (2016-2027)
7.3 Europe Tumor Immunotherapy Market Size by Application
7.3.1 Europe Tumor Immunotherapy Market Size by Application (2016-2021)
7.3.2 Europe Tumor Immunotherapy Market Size by Application (2022-2027)
7.3.3 Europe Tumor Immunotherapy Market Size by Application (2016-2027)
7.4 Europe Tumor Immunotherapy Market Size by Country
7.4.1 Europe Tumor Immunotherapy Market Size by Country (2016-2021)
7.4.2 Europe Tumor Immunotherapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunotherapy Market Size (2016-2027)
8.2 Asia-Pacific Tumor Immunotherapy Market Size by Type
8.2.1 Asia-Pacific Tumor Immunotherapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Tumor Immunotherapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Tumor Immunotherapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Tumor Immunotherapy Market Size by Application
8.3.1 Asia-Pacific Tumor Immunotherapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Tumor Immunotherapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Tumor Immunotherapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Tumor Immunotherapy Market Size by Region
8.4.1 Asia-Pacific Tumor Immunotherapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Tumor Immunotherapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Tumor Immunotherapy Market Size (2016-2027)
9.2 Latin America Tumor Immunotherapy Market Size by Type
9.2.1 Latin America Tumor Immunotherapy Market Size by Type (2016-2021)
9.2.2 Latin America Tumor Immunotherapy Market Size by Type (2022-2027)
9.2.3 Latin America Tumor Immunotherapy Market Size by Type (2016-2027)
9.3 Latin America Tumor Immunotherapy Market Size by Application
9.3.1 Latin America Tumor Immunotherapy Market Size by Application (2016-2021)
9.3.2 Latin America Tumor Immunotherapy Market Size by Application (2022-2027)
9.3.3 Latin America Tumor Immunotherapy Market Size by Application (2016-2027)
9.4 Latin America Tumor Immunotherapy Market Size by Country
9.4.1 Latin America Tumor Immunotherapy Market Size by Country (2016-2021)
9.4.2 Latin America Tumor Immunotherapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunotherapy Market Size (2016-2027)
10.2 Middle East & Africa Tumor Immunotherapy Market Size by Type
10.2.1 Middle East & Africa Tumor Immunotherapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Tumor Immunotherapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Tumor Immunotherapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Tumor Immunotherapy Market Size by Application
10.3.1 Middle East & Africa Tumor Immunotherapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Tumor Immunotherapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Tumor Immunotherapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Tumor Immunotherapy Market Size by Country
10.4.1 Middle East & Africa Tumor Immunotherapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Tumor Immunotherapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Tumor Immunotherapy Introduction
11.1.4 Roche Revenue in Tumor Immunotherapy Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Tumor Immunotherapy Introduction
11.2.4 Merck Revenue in Tumor Immunotherapy Business (2016-2021)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Tumor Immunotherapy Introduction
11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction
11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2016-2021)
11.4.5 Johnson & Johnson Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction
11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Tumor Immunotherapy Introduction
11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2016-2021)
11.6.5 AbbVie Recent Development
11.7 ELI Lilly
11.7.1 ELI Lilly Company Details
11.7.2 ELI Lilly Business Overview
11.7.3 ELI Lilly Tumor Immunotherapy Introduction
11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2016-2021)
11.7.5 ELI Lilly Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen Tumor Immunotherapy Introduction
11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2016-2021)
11.8.5 Amgen Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Tumor Immunotherapy Introduction
11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2016-2021)
11.9.5 AstraZeneca Recent Development
11.10 Bristol-Mysers Squibb
11.10.1 Bristol-Mysers Squibb Company Details
11.10.2 Bristol-Mysers Squibb Business Overview
11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction
11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2016-2021)
11.10.5 Bristol-Mysers Squibb Recent Development
11.11 Kite Pharma
11.11.1 Kite Pharma Company Details
11.11.2 Kite Pharma Business Overview
11.11.3 Kite Pharma Tumor Immunotherapy Introduction
11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2016-2021)
11.11.5 Kite Pharma Recent Development
11.12 Adaptimmune
11.12.1 Adaptimmune Company Details
11.12.2 Adaptimmune Business Overview
11.12.3 Adaptimmune Tumor Immunotherapy Introduction
11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2016-2021)
11.12.5 Adaptimmune Recent Development
11.13 Altor Bioscience Corporation
11.13.1 Altor Bioscience Corporation Company Details
11.13.2 Altor Bioscience Corporation Business Overview
11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction
11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2016-2021)
11.13.5 Altor Bioscience Corporation Recent Development
11.14 Cellectis
11.14.1 Cellectis Company Details
11.14.2 Cellectis Business Overview
11.14.3 Cellectis Tumor Immunotherapy Introduction
11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2016-2021)
11.14.5 Cellectis Recent Development
11.15 Juno Therapeutics
11.15.1 Juno Therapeutics Company Details
11.15.2 Juno Therapeutics Business Overview
11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction
11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2016-2021)
11.15.5 Juno Therapeutics Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Details
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Tumor Immunotherapy Introduction
11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2016-2021)
11.16.5 Takara Bio Recent Development
11.17 Unum Therapeutics
11.17.1 Unum Therapeutics Company Details
11.17.2 Unum Therapeutics Business Overview
11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction
11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2016-2021)
11.17.5 Unum Therapeutics Recent Development
11.18 Sunway
11.18.1 Sunway Company Details
11.18.2 Sunway Business Overview
11.18.3 Sunway Tumor Immunotherapy Introduction
11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2016-2021)
11.18.5 Sunway Recent Development
11.18 Junshi Bio
.1 Junshi Bio Company Details
.2 Junshi Bio Business Overview
.3 Junshi Bio Tumor Immunotherapy Introduction
.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2016-2021)
.5 Junshi Bio Recent Development
11.20 Cinda Bio
11.20.1 Cinda Bio Company Details
11.20.2 Cinda Bio Business Overview
11.20.3 Cinda Bio Tumor Immunotherapy Introduction
11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2016-2021)
11.20.5 Cinda Bio Recent Development
11.21 BeiGene
11.21.1 BeiGene Company Details
11.21.2 BeiGene Business Overview
11.21.3 BeiGene Tumor Immunotherapy Introduction
11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2016-2021)
11.21.5 BeiGene Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Tumor Immunotherapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tumor Infiltrating Lymphocyte (TIL) Treatment
Table 3. Key Players of Engineered T Cell Receptor (TCR) Therapy
Table 4. Key Players of Chimeric Antigen Receptor (CAR) T Cell Therapy
Table 5. Key Players of Natural Killer (NK) Cell Therapy
Table 6. Key Players of Other
Table 7. Global Tumor Immunotherapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Tumor Immunotherapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Tumor Immunotherapy Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Tumor Immunotherapy Market Share by Regions (2016-2021)
Table 11. Global Tumor Immunotherapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Tumor Immunotherapy Market Share by Regions (2022-2027)
Table 13. Tumor Immunotherapy Market Trends
Table 14. Tumor Immunotherapy Market Drivers
Table 15. Tumor Immunotherapy Market Challenges
Table 16. Tumor Immunotherapy Market Restraints
Table 17. Global Tumor Immunotherapy Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Tumor Immunotherapy Market Share by Players (2016-2021)
Table 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Immunotherapy as of 2020)
Table 20. Ranking of Global Top Tumor Immunotherapy Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Tumor Immunotherapy Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Tumor Immunotherapy Product Solution and Service
Table 24. Date of Enter into Tumor Immunotherapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Tumor Immunotherapy Revenue Market Share by Type (2016-2021)
Table 28. Global Tumor Immunotherapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Tumor Immunotherapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Tumor Immunotherapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Tumor Immunotherapy Revenue Market Share by Application (2016-2021)
Table 32. Global Tumor Immunotherapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Tumor Immunotherapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Tumor Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Tumor Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Tumor Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Tumor Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Tumor Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Tumor Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Tumor Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Tumor Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Tumor Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Tumor Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Tumor Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Tumor Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Tumor Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Tumor Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Tumor Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Tumor Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Tumor Immunotherapy Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Tumor Immunotherapy Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Tumor Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Tumor Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Tumor Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Tumor Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Tumor Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Tumor Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Tumor Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Tumor Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Tumor Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Tumor Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Tumor Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Tumor Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Tumor Immunotherapy Product
Table 67. Roche Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 68. Roche Recent Development
Table 69. Merck Company Details
Table 70. Merck Business Overview
Table 71. Merck Tumor Immunotherapy Product
Table 72. Merck Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 73. Merck Recent Development
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Tumor Immunotherapy Product
Table 77. Novartis Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 78. Novartis Recent Development
Table 79. Johnson & Johnson Company Details
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Tumor Immunotherapy Product
Table 82. Johnson & Johnson Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. GlaxoSmithKline Company Details
Table 85. GlaxoSmithKline Business Overview
Table 86. GlaxoSmithKline Tumor Immunotherapy Product
Table 87. GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 88. GlaxoSmithKline Recent Development
Table 89. AbbVie Company Details
Table 90. AbbVie Business Overview
Table 91. AbbVie Tumor Immunotherapy Product
Table 92. AbbVie Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 93. AbbVie Recent Development
Table 94. ELI Lilly Company Details
Table 95. ELI Lilly Business Overview
Table 96. ELI Lilly Tumor Immunotherapy Product
Table 97. ELI Lilly Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 98. ELI Lilly Recent Development
Table 99. Amgen Company Details
Table 100. Amgen Business Overview
Table 101. Amgen Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 102. Amgen Recent Development
Table 103. AstraZeneca Company Details
Table 104. AstraZeneca Business Overview
Table 105. AstraZeneca Tumor Immunotherapy Product
Table 106. AstraZeneca Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 107. AstraZeneca Recent Development
Table 108. Bristol-Mysers Squibb Company Details
Table 109. Bristol-Mysers Squibb Business Overview
Table 110. Bristol-Mysers Squibb Tumor Immunotherapy Product
Table 111. Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 112. Bristol-Mysers Squibb Recent Development
Table 113. Kite Pharma Company Details
Table 114. Kite Pharma Business Overview
Table 115. Kite Pharma Tumor Immunotherapy Product
Table 116. Kite Pharma Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 117. Kite Pharma Recent Development
Table 118. Adaptimmune Company Details
Table 119. Adaptimmune Business Overview
Table 120. Adaptimmune Tumor Immunotherapy Product
Table 121. Adaptimmune Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 122. Adaptimmune Recent Development
Table 123. Altor Bioscience Corporation Company Details
Table 124. Altor Bioscience Corporation Business Overview
Table 125. Altor Bioscience Corporation Tumor Immunotherapy Product
Table 126. Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 127. Altor Bioscience Corporation Recent Development
Table 128. Cellectis Company Details
Table 129. Cellectis Business Overview
Table 130. Cellectis Tumor Immunotherapy Product
Table 131. Cellectis Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 132. Cellectis Recent Development
Table 133. Juno Therapeutics Company Details
Table 134. Juno Therapeutics Business Overview
Table 135. Juno Therapeutics Tumor Immunotherapy Product
Table 136. Juno Therapeutics Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 137. Juno Therapeutics Recent Development
Table 138. Takara Bio Company Details
Table 139. Takara Bio Business Overview
Table 140. Takara Bio Tumor Immunotherapy Product
Table 141. Takara Bio Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 142. Takara Bio Recent Development
Table 143. Unum Therapeutics Company Details
Table 144. Unum Therapeutics Business Overview
Table 145. Unum Therapeutics Tumor Immunotherapy Product
Table 146. Unum Therapeutics Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 147. Unum Therapeutics Recent Development
Table 148. Sunway Company Details
Table 149. Sunway Business Overview
Table 150. Sunway Tumor Immunotherapy Product
Table 151. Sunway Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 152. Sunway Recent Development
Table 153. Junshi Bio Company Details
Table 154. Junshi Bio Business Overview
Table 155. Junshi Bio Tumor Immunotherapy Product
Table 156. Junshi Bio Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 157. Junshi Bio Recent Development
Table 158. Cinda Bio Company Details
Table 159. Cinda Bio Business Overview
Table 160. Cinda Bio Tumor Immunotherapy Product
Table 161. Cinda Bio Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 162. Cinda Bio Recent Development
Table 163. BeiGene Company Details
Table 164. BeiGene Business Overview
Table 165. BeiGene Tumor Immunotherapy Product
Table 166. BeiGene Revenue in Tumor Immunotherapy Business (2016-2021) & (US$ Million)
Table 167. BeiGene Recent Development
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor Immunotherapy Market Share by Type: 2020 VS 2027
Figure 2. Tumor Infiltrating Lymphocyte (TIL) Treatment Features
Figure 3. Engineered T Cell Receptor (TCR) Therapy Features
Figure 4. Chimeric Antigen Receptor (CAR) T Cell Therapy Features
Figure 5. Natural Killer (NK) Cell Therapy Features
Figure 6. Other Features
Figure 7. Global Tumor Immunotherapy Market Share by Application: 2020 VS 2027
Figure 8. Biopharmaceutical Company Case Studies
Figure 9. Hospital Case Studies
Figure 10. Universities And Other Scientific Research Institutions Case Studies
Figure 11. Other Case Studies
Figure 12. Tumor Immunotherapy Report Years Considered
Figure 13. Global Tumor Immunotherapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Tumor Immunotherapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Tumor Immunotherapy Market Share by Regions: 2020 VS 2027
Figure 16. Global Tumor Immunotherapy Market Share by Regions (2022-2027)
Figure 17. Global Tumor Immunotherapy Market Share by Players in 2020
Figure 18. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Immunotherapy as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2020
Figure 20. Global Tumor Immunotherapy Revenue Market Share by Type (2016-2021)
Figure 21. Global Tumor Immunotherapy Revenue Market Share by Type (2022-2027)
Figure 22. North America Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Tumor Immunotherapy Market Share by Type (2016-2027)
Figure 24. North America Tumor Immunotherapy Market Share by Application (2016-2027)
Figure 25. North America Tumor Immunotherapy Market Share by Country (2016-2027)
Figure 26. United States Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Tumor Immunotherapy Market Share by Type (2016-2027)
Figure 30. Europe Tumor Immunotherapy Market Share by Application (2016-2027)
Figure 31. Europe Tumor Immunotherapy Market Share by Country (2016-2027)
Figure 32. Germany Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Tumor Immunotherapy Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Tumor Immunotherapy Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Tumor Immunotherapy Market Share by Region (2016-2027)
Figure 42. China Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Tumor Immunotherapy Market Share by Type (2016-2027)
Figure 50. Latin America Tumor Immunotherapy Market Share by Application (2016-2027)
Figure 51. Latin America Tumor Immunotherapy Market Share by Country (2016-2027)
Figure 52. Mexico Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Tumor Immunotherapy Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Tumor Immunotherapy Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Tumor Immunotherapy Market Share by Country (2016-2027)
Figure 58. Turkey Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Tumor Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Roche Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 63. Novartis Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 64. Johnson & Johnson Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 66. AbbVie Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 67. ELI Lilly Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 68. Amgen Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 69. AstraZeneca Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 70. Bristol-Mysers Squibb Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 71. Kite Pharma Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 72. Adaptimmune Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 73. Altor Bioscience Corporation Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 74. Cellectis Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 75. Juno Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 76. Takara Bio Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 77. Unum Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 78. Sunway Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 79. Junshi Bio Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 80. Cinda Bio Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 81. BeiGene Revenue Growth Rate in Tumor Immunotherapy Business (2016-2021)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
世界の腫瘍免疫療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Tumor Immunotherapy Market The global Tumor Immunotherapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report mak…- 世界の循環腫瘍細胞（CTC）診断市場規模・現状・予測（2021年-2027年） Circulatingtumorcells(CTCs)arecellsthathaveshed intothevasculatureorlymphaticsfrom a primarytumorand arecarried around thebodyintheblood circulation. Market Analysis and Insights: Global Circulating Tumor Cell (CTC) Diagnostics Market The global Circulating Tumor Cell (CTC) Diagnostics market size i…
- 世界の循環腫瘍細胞（CTC）市場規模・現状・予測（2021年-2027年） Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potenti…
- 世界の免疫細胞療法市場規模・現状・予測（2021年-2027年） Immune therapy is a new class of cancer treatment designed to boost or enhance the body’s immune system to more efficiently target and destroy cancerous cells. Many experts believe that immunotherapy represents the most promising new cancer treatment since the development of chemotherapy. Market Ana…
- 世界の変形性関節症幹細胞治療市場規模・現状・予測（2021年-2027年） Osteoarthritis is one of the chronic conditions for joints which results in the breakdown and eventual loss of the cartilage of one or more joints. This can affect joints including hips, lower back, neck, small joints of the fingers, and the base of the thumb and big toe. The expected growth is beca…